TY - JOUR
T1 - Severe and Regionally Widespread Increases in Tissue Urea in the Human Brain Represent a Novel Finding of Pathogenic Potential in Parkinson's Disease Dementia
AU - Scholefield, Melissa
AU - Church, Stephanie J
AU - Xu, Jingshu
AU - Patassini, Stefano
AU - Roncaroli, Federico
AU - Hooper, Nigel M
AU - Unwin, Richard D
AU - Cooper, Garth J S
N1 - Funding Information:
This work was funded by grants from: Endocore Research Associates, New Zealand (60147); the Maurice and Phyllis Paykel Trust, New Zealand (3627036; and Travel funding for JX); Lottery Health New Zealand (3626585 and 3702766); the Maurice Wilkins Centre for Molecular Biodiscovery, New Zealand (Tertiary Education Commission 9341-3622506; and Doctoral Scholarship for JX); the Lee Trust, New Zealand; the University of Auckland (Doctoral Student PReSS funding JXU058); the Oakley Mental Health Research Foundation (3456030, 3627092, 3701339, 3703253, and 3702870); the Ministry of Business, Innovation & Employment, New Zealand (UOAX0815); the Neurological Foundation of New Zealand; the Medical Research Council (United Kingdom, MR/L010445/1 and MR/L011093/1); Alzheimer’s research United Kingdom (ARUK-PPG2014B-7); the University of Manchester, the CMFT, and the Northwest Regional Development Agency through a combined programme grant to CADET; and was facilitated by the Manchester Biomedical Research Centre and the Greater Manchester Comprehensive Local Research Network.
Funding Information:
We thank Michael Anderson for assisting in obtaining the tissues required for this study. PDD Cohort: Human tissue was obtained through the NIH Neurobiobank from the University of Miami Brain Endowment Bank. We thank both the banks and donors for supply of these tissues. Auckland AD and HD cohorts: We also thank the families of patients with Alzheimer?s disease who so generously supported this research through the donation of brain tissue to the New Zealand Neurological Foundation Douglas Human Brain Bank in the Centre for Brain Research, Faculty of Medical and Health.
Publisher Copyright:
Copyright © 2021 Scholefield, Church, Xu, Patassini, Roncaroli, Hooper, Unwin and Cooper.
PY - 2021/10/22
Y1 - 2021/10/22
N2 - Widespread elevations in brain urea have, in recent years, been reported in certain types of age-related dementia, notably Alzheimer's disease (AD) and Huntington's disease (HD). Urea increases in these diseases are substantive, and approximate in magnitude to levels present in uraemic encephalopathy. In AD and HD, elevated urea levels are widespread, and not only in regions heavily affected by neurodegeneration. However, measurements of brain urea have not hitherto been reported in Parkinson's disease dementia (PDD), a condition which shares neuropathological and symptomatic overlap with both AD and HD. Here we report measurements of tissue urea from nine neuropathologically confirmed regions of the brain in PDD and post-mortem delay (PMD)-matched controls, in regions including the cerebellum, motor cortex (MCX), sensory cortex, hippocampus (HP), substantia nigra (SN), middle temporal gyrus (MTG), medulla oblongata (MED), cingulate gyrus, and pons, by applying ultra-high-performance liquid chromatography-tandem mass spectrometry (UHPLC-MS/MS). Urea concentrations were found to be substantively elevated in all nine regions, with average increases of 3-4-fold. Urea concentrations were remarkably consistent across regions in both cases and controls, with no clear distinction between regions heavily affected or less severely affected by neuronal loss in PDD. These urea elevations mirror those found in uraemic encephalopathy, where equivalent levels are generally considered to be pathogenic, and those previously reported in AD and HD. Increased urea is a widespread metabolic perturbation in brain metabolism common to PDD, AD, and HD, at levels equal to those seen in uremic encephalopathy. This presents a novel pathogenic mechanism in PDD, which is shared with two other neurodegenerative diseases.
AB - Widespread elevations in brain urea have, in recent years, been reported in certain types of age-related dementia, notably Alzheimer's disease (AD) and Huntington's disease (HD). Urea increases in these diseases are substantive, and approximate in magnitude to levels present in uraemic encephalopathy. In AD and HD, elevated urea levels are widespread, and not only in regions heavily affected by neurodegeneration. However, measurements of brain urea have not hitherto been reported in Parkinson's disease dementia (PDD), a condition which shares neuropathological and symptomatic overlap with both AD and HD. Here we report measurements of tissue urea from nine neuropathologically confirmed regions of the brain in PDD and post-mortem delay (PMD)-matched controls, in regions including the cerebellum, motor cortex (MCX), sensory cortex, hippocampus (HP), substantia nigra (SN), middle temporal gyrus (MTG), medulla oblongata (MED), cingulate gyrus, and pons, by applying ultra-high-performance liquid chromatography-tandem mass spectrometry (UHPLC-MS/MS). Urea concentrations were found to be substantively elevated in all nine regions, with average increases of 3-4-fold. Urea concentrations were remarkably consistent across regions in both cases and controls, with no clear distinction between regions heavily affected or less severely affected by neuronal loss in PDD. These urea elevations mirror those found in uraemic encephalopathy, where equivalent levels are generally considered to be pathogenic, and those previously reported in AD and HD. Increased urea is a widespread metabolic perturbation in brain metabolism common to PDD, AD, and HD, at levels equal to those seen in uremic encephalopathy. This presents a novel pathogenic mechanism in PDD, which is shared with two other neurodegenerative diseases.
KW - Alzheimer’s disease (AD)
KW - Huntington’s disease (HD)
KW - Parkinson’s disease dementia (PDD)
KW - mass spectrometry-LC-MS/MS
KW - metabolomics (OMICS)
KW - urea-analysis
UR - https://doi.org/10.21203/rs.3.rs-435222/v1
U2 - 10.3389/fnmol.2021.711396
DO - 10.3389/fnmol.2021.711396
M3 - Article
C2 - 34751215
SN - 1662-5099
VL - 14
JO - Frontiers in Molecular Neuroscience
JF - Frontiers in Molecular Neuroscience
M1 - 711396
ER -